Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease

By Ruff Christian T   Giugliano Robert   Morrow David A  

Future Cardiology, Vol. 2, Iss. 1, 2006-01 ,pp. : 85-91

Future Medicine

Access to resources Recommend Favorite

Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design

By Povsic T.  

Journal of Thrombosis and Thrombolysis, Vol. 32, Iss. 1, 2011-07 ,pp. : 21-31

Springer Publishing Company

Access to resources Recommend Favorite

The aptamer ARC1779 is a potent and specific inhibitor of von willebrand factor mediated ex vivo platelet function in acute myocardial infarction

By Spiel Alexander   Mayr Florian   Ladani Nathalie   Wagner Patricia   Schaub Robert   Gilbert James   Jilma Bernd  

Platelets, Vol. 20, Iss. 5, 2009-08 ,pp. : 334-340

Informa Healthcare

Access to resources Recommend Favorite

Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark

By Henriksson Martin   Nikolic Elisabet   Ohna Audun   Wallentin Lars   Janzon Magnus  

Scandinavian Cardiovascular Journal, Vol. 48, Iss. 3, 2014-06 ,pp. : 138-147

Informa Healthcare

Access to resources Recommend Favorite

Acute Coronary Syndrome and its Antithrombotic Treatment: Focus on Aspirin and Clopidogrel Resistance

By  

Current Vascular Pharmacology, Vol. 7, Iss. 2, 2009-04 ,pp. : 198-208

Bentham Science Publishers

Access to resources Recommend Favorite